Bio-Rad Labs (BIO) Tops Q3 EPS by 11c
Get Alerts BIO Hot Sheet
EPS Growth %: -30.8%
Financial Fact:
Research and development expense: 52.17M
Today's EPS Names:
DGICA, UXIN, TOWN, More
Join SI Premium – FREE
Bio-Rad Labs (NYSE: BIO) reported Q3 EPS of $0.62, $0.11 better than the analyst estimate of $0.51. Revenue for the quarter came in at $508.7 million versus the consensus estimate of $480.6 million.
"We are pleased with a strong sales performance in the third quarter, in particular, our life science business, with nearly 20 percent currency-neutral growth," said Norman Schwartz, Bio-Rad President and Chief Executive Officer. "Continued investments in our operations have affected profitability for the first nine months of the year, but these investments are necessary to support our growth."
For earnings history and earnings-related data on Bio-Rad Labs (BIO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- West Bancorporation (WTBA) Tops Q1 EPS by 8c
- Netlist (NLST) Misses Q1 EPS by 1c
Create E-mail Alert Related Categories
Earnings, Management CommentsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!